PrecisionLife enters into R&D collaboration with multiple goals

OXFORD, UK, Dec. 14, 2022 (GLOBE NEWSWIRE) — PrecisionLife Limited (“PrecisionLife”), a global Techbio company providing the deepest insights into disease biology to develop novel precision medicines for chronic diseases, today announced it has completed a multi-target -Discovery and validation partnership with Ono Pharmaceutical Co., Ltd. (“Ono”), a research and development focused pharmaceutical company. The R&D collaboration will leverage PrecisionLife’s insights gained through combinatorial analytics to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono.

PrecisionLife is a global leader in analyzing multimodal datasets, including genomic, clinical, and epidemiological data, to accurately stratify patients and understand subgroup relevant disease risks and drivers. The Company has used this unique disease insight to discover new therapeutic targets for unmet medical needs, biomarkers to select the right patients for more targeted clinical trials, retrospective analysis of clinical trials, generation of clinical risk assessments and identification of indication expansion opportunities.

Under the terms of the agreement, PrecisionLife will apply its combinatorial analysis platform to patient datasets to identify multiple new therapeutic targets for Ono’s development. PrecisionLife will leverage its significant drug discovery expertise to provide Ono with a clear rationale for target selection with genetic validation and mechanistic hypotheses, preclinical validation and biomarkers for patient stratification to optimize clinical development of the compounds. Ono will select targets from PrecisionLife’s recommendations and will acquire worldwide rights to develop and commercialize a pharmaceutical product that acts on the target.

This research collaboration is an example of PrecisionLife’s capabilities in precision medicine and drug discovery for complex chronic diseases that have significant unmet medical needs. PrecisionLife has analyzed over 40 high-value disease indications and maintains a comprehensive portfolio of insights and patented discoveries in its DiseaseBank™ repository.

READ :  Despite a slight decline, biologists expect manatee deaths to continue into 2023

“We are excited to partner with Ono on this precise neuroscience collaboration as it brings together our novel insights into the complex biology of disease with Ono’s deep expertise in drug development.said Dr. Steve Gardner, CEO of PrecisionLife. “We expect this will yield powerful new treatment options that address the currently unmet medical needs of important patient subgroups in some of the most challenging common CNS disorders.

We value PrecisionLife’s unique combinatorial analysis platform for discovering new therapies that address specific medical needs in complex central nervous system disorderssaid Toichi Takino, Ono’s Senior Executive Officer/Executive Director, Discovery & Research. “Through this new collaboration, we expect to increase efficiency in the search for new drug candidates that offer patients much-needed new therapeutic options.”

About Ono Pharmaceutical Co.,Ltd

Ono Pharmaceutical Co.,Ltd. headquartered in Osaka, Japan, is a research and development-based pharmaceutical company dedicated to the development of innovative medicines in specific areas. Ono focuses its research on oncology, immunology, neurology and specialty research with high unmet medical needs as priority areas for the discovery and development of innovative medicines. For more information, please visit the company’s website at

About PrecisionLife

PrecisionLife is a pioneering techbio company transforming the way we predict, prevent and treat chronic disease. Its unique combinatorial analysis approach generates more insights from patient data than any other method, revealing the drivers of complex disease biology and stratifying patients with unprecedented resolution.

This deeper understanding of disease biology fuels PrecisionLife’s innovation engine for patient-centric drug discovery, low-risk clinical development and accurate diagnosis, ushering in a new age of better, more personalized therapy options – improving health for everyone.

READ :  Widespread Adoption of AI Presents Opportunities

PrecisionLife has developed an in-house pipeline of novel early-stage drug discovery targets with patient stratification biomarkers and precise repositioning facilities for co-development with biopharma partners in over 40 chronic diseases.

Visit for more information

Leave a Reply

Your email address will not be published. Required fields are marked *